TO RECOGNIZE AND CELEBRATE MAY 2026 AS AMYOTROPHIC LATERAL SCLEROSIS AWARENESS MONTH IN THIS STATE.
HR 1017 is a simple House resolution that designates May 2026 as Amyotrophic Lateral Sclerosis (ALS) Awareness Month in Arkansas. The resolution describes ALS, also known as Lou Gehrig’s disease, as a fatal progressive neurodegenerative disease and notes its effects on patients, families, caregivers, and communities. It also highlights the lack of a known cure, the importance of clinical trials, assistive technologies, durable medical equipment, and access to new therapies, and the role of organizations such as the ALS Association in funding research and providing support services.
The resolution does not create a regulatory program, appropriate funds, or amend any Arkansas statutes. Its practical effect is symbolic: it formally recognizes ALS Awareness Month and encourages public awareness, support for research, advocacy for increased funding, and solidarity with those affected by the disease. The measure was read and adopted, indicating it moved through the House without recorded opposition in the available history.
The general sentiment around the bill is strongly supportive and compassionate. The text emphasizes the severity of ALS, the burden on families and caregivers, and the need to increase awareness among the public and healthcare providers. It also frames the resolution as a way to honor people living with ALS and to encourage continued research toward better treatments and a cure.
There is little apparent contention in the available materials. Because the bill is a commemorative resolution rather than a policy change, there are no recorded committee debates or votes showing disagreement. The only substantive policy-related themes are broad support for research funding, access to therapies and equipment, and recognition of the elevated risk among military veterans, but these are presented as reasons for support rather than disputed issues.
HR 1017 has no direct effect on Arkansas statutory law, appropriations, or agency duties. It is a nonbinding House resolution that formally recognizes May 2026 as ALS Awareness Month and encourages advocacy, research support, and public awareness. Its impact is primarily ceremonial and educational, aimed at affected individuals, families, caregivers, healthcare providers, researchers, and advocacy organizations.
The sentiment is uniformly positive and supportive. The resolution uses solemn, advocacy-oriented language to emphasize the seriousness of ALS, the absence of a cure, and the need for research and community support. The available action history shows the measure was read and adopted, with no recorded dissent or controversy in the provided materials.
No notable contention appears in the provided record. The resolution is noncontroversial on its face and does not alter law or spending. The only potentially policy-relevant themes are calls for increased research funding, access to therapies and assistive technology, and recognition of the higher incidence among military veterans, but none of these appear to have generated opposition in the available discussion or voting history.